Tag Archive for: Immuno-oncology

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

/in

First patient dosed in France, expanding the DOMISOL study beyond Australia DT‑7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program Montreal, Canada – Strasbourg, France – Boston, United States, April 9, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

Read more

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

/in

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance Montreal, Canada – Strasbourg, France – Boston, United States, March 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

Read more

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

/in

Financing led by Investissement Québec with continued support from long-standing investors Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients Montreal, Canada – Strasbourg, France – Boston, United States, February 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced […]

Read more

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies

/in

Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of corporate growth Kainova champions scientific agility, bold ambition, and unity of purpose Montreal, Canada, Strasbourg, France, Boston, USA, January 12, 2026: Kainova Therapeutics (“Kainova” or “the Company”), a catalyst for breakthrough treatments for patients in immuno-oncology and inflammation, today announced a transformative rebrand. The new […]

Read more

Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer

/in

Internationally recognized clinical strategist with proven track record in translating innovation into clinical impact joins Domain to advance its GPCR-targeting pipeline Appointment comes at a pivotal moment, following the initiation of Phase I/II development of DT-7012, a Treg-depleting anti-CCR8 antibody candidate Strasbourg, France – Montreal, Canada – Boston, United States, November 13, 2025: Domain Therapeutics […]

Read more
© Optimum Strategic Communications.